,54 It also has been shown in these studies that the protective effects of the PPARγ inhibitor were associated with a marked protection against inflammatory alterations associated with the development of MASLD, for example, the induction of proinflammatory cytokines and an increase in NO in liver tissue and cell culture supernatants.10 Here, PPARG is linked to metabolic dysfunction-associated steatotic liver disease.